Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Dose Escalation and Expansion Study of SC-003 as a Single-Agent and in Combination With ABBV-181 in Subjects With Platinum-Resistant/ Refractory Ovarian Cancer

NCT02539719 is registered in ClinicalTrials.gov with Stemcentrx as lead sponsor.

NCT NCT02539719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02539719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Dose Escalation and Expansion Study of SC-003 as a Single-Agent and in Combination With ABBV-181 in Subjects With Platinum-Resistant/ Refractory Ovarian Cancer
Lead sponsor
Stemcentrx
Phase
Phase 1
Overall status
Terminated
Start date
August 31, 2015
Completion date
January 2, 2019
Enrollment
74 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer